Search clinical trials for: BMS-650032 (NS3 Protease Inhibitor)

Total 6968 results

Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
Bristol-Myers Squibb

Completed

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Completed

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Chronic Hepatitis C

France, United States, Puerto Rico
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States
Genentech, Inc.

Completed

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Spain, United States, France
Humanity and Health Research Centre
Emory University; Beijing 302 Hospital

Completed

Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Chronic Hepatitis C Infection

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Bristol-Myers Squibb

Completed

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

Atrial Fibrillation | Atrial Flutter

Australia, Brazil, China, France, Germany, India, Italy, Korea, Republic of, Mexico, Russian Federation, Sweden, Taiwan, Turkey, United States, Hong Kong, Spain, Argentina, Canada, Puerto Rico, Colombia, Denmark, Austria, Belgium, Hun... and more
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Bristol-Myers Squibb

Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

Hepatitis C Virus

United States, Germany, Italy, Korea, Republic of, Sweden, Russian Federation, Canada, France, Argentina, Switzerland, Denmark, Taiwan, Netherlands, Spain, Mexico
Bristol-Myers Squibb
Pfizer

Completed

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Thromboembolism

United States, Canada, Mexico, Israel, Australia
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Bristol-Myers Squibb
Pfizer

Completed

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

NonValvular Atrial Fibrillation

Japan
Bristol-Myers Squibb
Pfizer

Completed

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Anticoagulation

India
Bristol-Myers Squibb
Pfizer

Terminated

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Venous Thromboembolism

United States, Belgium, Canada, Mexico, Netherlands
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Healthy Volunteers

United States
Bristol-Myers Squibb
Pfizer

Completed

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Venous Thrombosis

Australia, Czech Republic, India, Italy, Korea, Republic of, Mexico, United Kingdom, United States, Hong Kong, Spain, France, Argentina, Brazil, Russian Federation, Austria, Denmark, Germany, Israel, Portugal, Romania, Singapore, ... and more
Bristol-Myers Squibb

Completed

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (AEGEAN)

Non-valvular Atrial Fibrillation

Belgium, France, Italy, Spain, Switzerland, Germany, United Kingdom
Bristol-Myers Squibb
Ontario Clinical Oncology Group (OCOG)

Completed

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Cancer | Thrombosis | Pulmonary Embolism

United States, Canada
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Healthy Subjects

United States
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Healthy Volunteers

United States
Neosil, Inc.

Unknown

Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Androgenetic Alopecia

Germany
Neosil, Inc.

Completed

Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Androgenetic Alopecia

Germany
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Drug Interaction Oral Contraceptive Pill (OCP)

Hepatitis C Virus

United States
Bristol-Myers Squibb

No longer available

Atazanavir for HIV Infected Individuals: An Early Access Program

HIV Infections

United States, Puerto Rico
The Rogosin Institute
Weill Medical College of Cornell University

Withdrawn

Velcade for Proliferative Lupus Nephritis

Proteinuria | Lupus Nephritis | Hematuria

United States
University of Florence
Azienda Ospedaliero-Universitaria Careggi; Istituto per lo Studio, la Prevenzione...

Recruiting

SLPI for Prostate Cancer

Prostate Cancer | Prostatic Neoplasm

Italy
Bristol-Myers Squibb

Completed

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness (ADOPT)

Venous Thrombosis | Pulmonary Embolism

Argentina, Australia, France, India, Korea, Republic of, United Kingdom, United States, Spain, Mexico, Colombia, Austria, Denmark, Canada, Germany, Israel, Peru, Singapore, Sweden, Poland, Belgium, Hungary, Italy, Russian Federation, ... and more
National Institute of Dental and Craniofacial Research...

Completed

Effects of Topical SLPI on Skin Wounds

Healthy | Wound Healing

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Malignant Neoplasm | Portal Vein Thrombosis | Metastatic Malignant Neoplasm | Cerebral Vein Thrombosis | Renal Vein Thrombosis | Gonadal Thrombosis | Hepatic Thrombosis | Mesenteric Thrombosis | Splenic Thrombosis

United States
ViiV Healthcare

Completed

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Infection, Human Immunodeficiency Virus

United States, Spain, Peru, Romania, Colombia, South Africa, Germany, Russian Federation, Argentina, Mexico
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Steven E. Coutre
National Cancer Institute (NCI)

Terminated

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
Bristol-Myers Squibb
Pfizer; Duke Clinical Research Institute

Terminated

Phase III Acute Coronary Syndrome (APPRAISE-2)

Acute Coronary Syndrome

Argentina, China, India, Japan, Korea, Republic of, Mexico, Poland, South Africa, Sweden, United States, Chile, Spain, United Kingdom, Australia, Brazil, Colombia, Austria, Denmark, Germany, Belgium, Hungary, Israel, Peru, Romania, Russian... and more
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
American Society of Hematology

Active, not recruiting

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Benign and Malignant Hematologic Diseases

United States
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Hematologic Cancer

Refractory Hematologic Cancer

United States

Search clinical trials for: BMS-650032 (NS3 Protease Inhibitor)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations